2024년에 130억 달러로 추정되는 세계의 첨단 치료제 시장은 2024-2030년에 CAGR 11.8%로 성장하며, 2030년에는 254억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 조직공학 제품은 CAGR 12.5%를 기록하며, 분석 기간 종료시에는 105억 달러에 달할 것으로 예측됩니다. 세포치료 분야의 성장률은 분석 기간의 CAGR로 11.1%로 추정됩니다.
미국 시장은 56억 달러로 추정, 중국은 CAGR 10.2%로 성장 예측
미국의 첨단 치료제 시장은 2024년에는 56억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 11억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 10.2%가 됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 9.9%와 8.8%로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.9%로 성장할 것으로 예측됩니다.
세계의 첨단 치료제 시장 - 주요 동향과 촉진요인 정리
첨단치료제(ATMPs)는 첨단 생물학적 기법을 통해 질병을 치료, 진단, 예방하도록 설계된 유전자치료제, 세포치료제, 조직공학 제품을 포괄하는 의료 혁신의 최첨단을 대표하는 분야입니다. 치료하기 어렵거나 불가능한 질병에 대한 획기적인 치료법을 제공합니다. 이러한 치료법은 세포의 유전자를 변경하거나 신체 자체의 복구 메커니즘을 이용하거나 손상된 조직을 대체함으로써 고도로 맞춤화되고 치료 가능성이 있는 치료제를 제공합니다. 엄격한 규제 절차를 거칩니다.
생명공학의 눈부신 발전과 유전자 및 세포 메커니즘에 대한 깊은 이해로 인해 ATMP 분야는 급속도로 발전하고 있으며, CRISPR-Cas9 유전자 편집, 인공줄기세포(iPSC), 첨단 조직 스캐폴딩 기술 등의 개발로 효과적이고 표적화된 치료법을 개발할 수 있는 가능성이 확대되고 있습니다. FDA 및 EMA와 같은 규제기관에서 ATMP에 대한 임상시험이 증가하고 승인에 성공하면서 ATMP의 치료 가능성과 시장성이 더욱 부각되고 있습니다. 학계, 생명공학 기업, 제약사 간의 공동 연구는 개발 파이프라인을 가속화하고 더 많은 ATMP가 상용화에 가까워지고 있습니다. 또한 제조 기술 및 확장 가능한 생산 공정의 발전으로 이러한 치료제를 보다 쉽게 이용할 수 있고 비용 효율성이 높아지고 있습니다.
ATMP 시장의 성장은 몇 가지 요인에 의해 이루어지고 있습니다. 첫째, 기존의 치료법으로는 충분히 대처할 수 없는 만성질환과 유전성 질환의 유병률이 증가하면서 ATMP와 같은 혁신적인 치료제에 대한 수요가 증가하고 있습니다. 둘째, 생명공학 및 유전공학의 눈부신 발전으로 보다 효과적이고 맞춤화된 ATMP의 개발이 가능해졌습니다. 셋째, 생명공학 기업 및 제약회사들의 연구개발에 대한 막대한 투자가 새로운 ATMP의 발견과 상용화를 가속화하고 있습니다. 또한 획기적인 치료제에 대한 양호한 규제 환경과 신속한 승인 경로가 ATMP의 빠른 시장 진입을 촉진하고 있습니다. 마지막으로 ATMP의 제조 및 유통 인프라의 확대와 더불어 첨단 치료의 이점에 대한 환자와 의사의 인식이 높아지면서 시장 성장을 더욱 촉진하고 있습니다.
부문
제품 유형(조직공학 제품, 세포치료, 유전자 치료, CAR-T요법)
조사 대상 기업의 예
Bluebird Bio Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
JCR Pharmaceuticals Co. Ltd.
Kolon TissueGene, Inc.
MEDIPOST Co., Ltd.
Novartis AG
Organogenesis Inc.
Spark Therapeutics, Inc.
UniQure N.V.
Vericel Corporation
AI 통합
당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
KSA
영문 목차
영문목차
Global Advanced Therapy Medicinal Products Market to Reach US$25.4 Billion by 2030
The global market for Advanced Therapy Medicinal Products estimated at US$13.0 Billion in the year 2024, is expected to reach US$25.4 Billion by 2030, growing at a CAGR of 11.8% over the analysis period 2024-2030. Tissue Engineered Products, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$10.5 Billion by the end of the analysis period. Growth in the Cell Therapy segment is estimated at 11.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$5.6 Billion While China is Forecast to Grow at 10.2% CAGR
The Advanced Therapy Medicinal Products market in the U.S. is estimated at US$5.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.9% and 8.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.
Advanced Therapy Medicinal Products (ATMPs) represent a frontier in medical innovation, encompassing gene therapies, cell therapies, and tissue-engineered products designed to treat, diagnose, or prevent diseases through advanced biological methods. ATMPs offer groundbreaking treatments for conditions that are currently difficult or impossible to treat with conventional medicines, including various cancers, genetic disorders, and degenerative diseases. These therapies work by modifying the genetic makeup of cells, harnessing the body's own repair mechanisms, or replacing damaged tissues, thus providing highly personalized and potentially curative treatments. The development and approval of ATMPs are subject to stringent regulatory processes, ensuring their safety, efficacy, and quality.
The field of ATMPs has seen rapid advancements due to significant progress in biotechnology and a deeper understanding of genetic and cellular mechanisms. Innovations such as CRISPR-Cas9 gene editing, induced pluripotent stem cells (iPSCs), and advanced tissue scaffolding techniques have expanded the possibilities for developing effective and targeted therapies. The growing number of clinical trials and successful approvals of ATMPs by regulatory bodies such as the FDA and EMA highlight their therapeutic potential and market viability. Collaborations between academic institutions, biotech companies, and pharmaceutical giants are accelerating the development pipeline, bringing more ATMPs closer to commercialization. Additionally, advancements in manufacturing technologies and scalable production processes are making these therapies more accessible and cost-effective.
The growth in the ATMP market is driven by several factors. Firstly, the increasing prevalence of chronic and genetic diseases, which are often inadequately addressed by traditional treatments, is driving demand for innovative therapies like ATMPs. Secondly, significant advancements in biotechnology and genetic engineering are enabling the development of more effective and personalized ATMPs. Thirdly, substantial investments in research and development by biotech firms and pharmaceutical companies are accelerating the discovery and commercialization of new ATMPs. Additionally, the favorable regulatory environment and expedited approval pathways for breakthrough therapies are facilitating faster market entry for ATMPs. Lastly, the growing patient and physician awareness of the benefits of advanced therapies, coupled with the expanding infrastructure for ATMP manufacturing and distribution, are further propelling the market's growth.
SCOPE OF STUDY:
The report analyzes the Advanced Therapy Medicinal Products market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Tissue Engineered Products, Cell Therapy, Gene Therapy, CAR-T Therapy)
Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.
Select Competitors (Total 190 Featured) -
Bluebird Bio Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
JCR Pharmaceuticals Co. Ltd.
Kolon TissueGene, Inc.
MEDIPOST Co., Ltd.
Novartis AG
Organogenesis Inc.
Spark Therapeutics, Inc.
UniQure N.V.
Vericel Corporation
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
A Prelude to Advanced Therapy Medicinal Products (ATMP)
ATMPs' Costs and Availability
Global Economic Outlook
Tariff Impact on Global Supply Chain Patterns
Global Market Prospects and Outlook
Advanced Therapy Medicinal Products Market Poised to Witness Rapid Growth
Growth Drivers and Challenges
ATMP Marketing Authorisations: An Insight
North America and Europe Dominate, Asia-Pacific to Exhibit Fastest Growth
Competition
Recent Market Activity
Advanced Therapy Medicinal Products - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Geriatric Population and Subsequent Growth in Prevalence of Neurological Disorders Drive Market Demand
Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Regenerative Medicine: A Promising Area for Advanced Therapy Medicinal Products
Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration
Rising Demand for Gene Therapy Spurs Market Expansion
List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
Top Ten Genetic Diseases Worldwide
Oncology Represents the Largest Indication for Gene Therapy
Uptrend in Healthcare Spending Creates Fertile Environment
Expanding Role of Advanced Therapy Medicinal Products Market in Personalized Medicine
Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
Biotech Research Spending Patterns Steer Momentum
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Advanced Therapy Medicinal Products Market Analysis of Annual Sales in US$ Million for Years 2022 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World 6-Year Perspective for Advanced Therapy Medicinal Products by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Tissue Engineered Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 5: World 6-Year Perspective for Tissue Engineered Products by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 7: World 6-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World 6-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for CAR-T Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 11: World 6-Year Perspective for CAR-T Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 12: USA Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 13: USA 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
CANADA
TABLE 14: Canada Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 15: Canada 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
JAPAN
Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 16: Japan Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 17: Japan 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
CHINA
Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 18: China Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 19: China 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
EUROPE
Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 20: Europe Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: Europe 6-Year Perspective for Advanced Therapy Medicinal Products by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
TABLE 22: Europe Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 23: Europe 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
FRANCE
Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 24: France Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 25: France 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
GERMANY
Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 26: Germany Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: Germany 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
ITALY
TABLE 28: Italy Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 29: Italy 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
UNITED KINGDOM
Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 30: UK Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 31: UK 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
REST OF EUROPE
TABLE 32: Rest of Europe Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Rest of Europe 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
ASIA-PACIFIC
Advanced Therapy Medicinal Products Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 34: Asia-Pacific Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 35: Asia-Pacific 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
REST OF WORLD
TABLE 36: Rest of World Recent Past, Current & Future Analysis for Advanced Therapy Medicinal Products by Type - Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 37: Rest of World 6-Year Perspective for Advanced Therapy Medicinal Products by Type - Percentage Breakdown of Value Revenues for Tissue Engineered Products, Cell Therapy, Gene Therapy and CAR-T Therapy for the Years 2025 & 2030
